 This is a multicenter when more than one hospital or medical school team work on a medical research study, prospective study following participants forward in time, open-label all people know the identity of the intervention study of infliximab in pediatric participants with inflammatory bowel disease. The study consists of 3 Phases: screening Phase 2 Weeks, open-label treatment Phase 56 Weeks and follow up safety Phase 8 Weeks. The duration of participation in the study for each participant is approximately 66 Weeks including screening period. Participants efficacy and safety outcomes will be monitored throughout the study. 